No abstract

No abstract

No abstract

or later. Prophylactic treatment with dexamethasone mouthwash was initiated in 50% of patients (from January 2017). All patients began treatment with everolimus at a dose of 10 mg daily. Of these, 38% (n=9) required a reduction to 5 mg daily due to toxicity: intense asthenia (n=3), pneumonitis (n=1), skin rash (n=1), oedema in the lower limbs (n=1), thrombopenia (n=1), neutropenia (n=1) and persistent nausea and vomiting (n=1). A total of 88% of patients discontinued treatment due to radiological progression of the disease. The average treatment duration was 5.9 months. In no case was the treatment terminated due to adverse effects. Regarding the efficacy of dexamethasone mouthwash, in patients who did not use the oral solution (n=12), the incidence of stomatitis was 67% (grade 1, n=5; grade 2, n=3). This delayed the antineoplastic treatment in 2 patients (25%; n=2). In patients who used dexamethasone mouthwash (n=12), one patient presented with stomatitis (grade 1). The use of dexamethasone mouthwash 0.1 mg/mL was associated with a statistically significant decrease in the incidence of stomatitis (c 2 <0.05). No adverse effects associated with the oral solution were detected. Conclusion and relevance Prophylactic use of dexamethasone mouthwash reduced the incidence and severity of stomatitis in patients receiving everolimus-exemestane.